Common Contracts
2 similar Development and Commercialization Agreement contracts by Bioverativ Inc.
SECOND AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between Swedish Orphan Biovitrum AB (publ) and Biogen Idec Hemophilia Inc. CONFIDENTIAL TREATMENT REQUESTED FOIA EXEMPTION CLAIMED AND PRIOR NOTIFICATION REQUESTED BEFORE ANY...Development and Commercialization Agreement • December 20th, 2016 • Bioverativ Inc. • Pharmaceutical preparations • New York
THIS SECOND AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”), dated as of April 10, 2014 (the “Effective Date”) is entered into between Swedish Orphan Biovitrum AB (publ), a Swedish corporation having a place of business at Tomtebodavägen 23A, Solna, Stockholm, SE-112 76, Sweden (“Sobi”) and Biogen Idec Hemophilia Inc., a Delaware corporation having a place of business at 14 Cambridge Center, Cambridge, MA 02142 USA (“Biogen Idec”). Each of Sobi and Biogen Idec shall be referred to herein as a “Party,” and collectively as the “Parties”.
SECOND AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between Swedish Orphan Biovitrum AB (publ) and Biogen Idec Hemophilia Inc. CONFIDENTIAL TREATMENT REQUESTED FOIA EXEMPTION CLAIMED AND PRIOR NOTIFICATION REQUESTED BEFORE ANY...Development and Commercialization Agreement • October 21st, 2016 • Bioverativ Inc. • Pharmaceutical preparations • New York
THIS SECOND AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”), dated as of April 10, 2014 (the “Effective Date”) is entered into between Swedish Orphan Biovitrum AB (publ), a Swedish corporation having a place of business at Tomtebodavägen 23A, Solna, Stockholm, SE-112 76, Sweden (“Sobi”) and Biogen Idec Hemophilia Inc., a Delaware corporation having a place of business at 14 Cambridge Center, Cambridge, MA 02142 USA (“Biogen Idec”). Each of Sobi and Biogen Idec shall be referred to herein as a “Party,” and collectively as the “Parties”.
